Anti-inflammatory treatment with pentoxifylline improves HIV-related endothelial dysfunction: A pilot study

Samir K. Gupta, Raymond M. Johnson, Kieren J. Mather, Matthias Clauss, Jalees Rehman, Chandan Saha, Zeruesenay Desta, Michael P. Dubé

Research output: Contribution to journalArticle

14 Scopus citations

Abstract

We performed a single-arm, open-label pilot trial of the anti-inflammatory drug pentoxifylline to reduce systemic inflammation and improve endothelial function, measured by flow-mediated dilation of the brachial artery, in HIV-infected patients not requiring antiretroviral therapy. Pentoxifylline significantly reduced circulating levels of vascular cell adhesion molecule-1 and interferon-gamma-induced protein and significantly improved endothelial function during the 8-week trial. Pentoxifylline may reverse HIV-related endothelial dysfunction by directly inhibiting the endothelial leukocyte adhesion pathway.

Original languageEnglish (US)
Pages (from-to)1377-1380
Number of pages4
JournalAIDS
Volume24
Issue number9
DOIs
StatePublished - Jun 1 2010

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Anti-inflammatory treatment with pentoxifylline improves HIV-related endothelial dysfunction: A pilot study'. Together they form a unique fingerprint.

  • Cite this